Evidence map›Paper›PMID 17384676›Full record

ArticleOncogene2007

DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118.

Y Sekine, O Ikeda, Y Hayakawa, S Tsuji, S Imoto, N Aoki, K Sugiyama, T Matsuda

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 81 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Y SekineDepartment of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
O Ikeda
Y Hayakawa
S Tsuji
S Imoto
N Aoki
K Sugiyama
T Matsuda
Hokkaido University · JPMie University · JPToyo Institute of Food Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the previous study, we demonstrated the involvement of dual specificity phosphatase 22 (DUSP22/LMW-DSP2) in regulating the leukemia inhibitory factor/interleukin-6/signal transducer and activator of transcription 3-mediated signaling pathway. In this study, we show beta-estradiol (E2)-induced DUSP22 mRNA expression in estrogen receptor alpha (ERalpha)-positive breast cancer cells, whereas E2-induced phosphorylation and activation of ERalpha was suppressed by overexpression of DUSP22 but not catalytically inactive mutants. Furthermore, small-interfering RNA-mediated reduction of DUSP22 expression enhanced ERalpha-mediated transcription and endogenous gene expression. In fact, DUSP22 associated with ERalpha in vivo and both endogenous proteins interacted in ERalpha-positive breast cancer T47D cells. These results strongly suggest that DUSP22 acts as a negative regulator of the ERalpha-mediated signaling pathway.

Indexed as

Breast NeoplasmsDual-Specificity PhosphatasesEstradiolEstrogen Receptor alphaFemaleHeLa CellsHumansMitogen-Activated Protein Kinase PhosphatasesPhosphoprotein PhosphatasesPhosphoserinePolymerase Chain ReactionProtein Tyrosine PhosphatasesRNA, MessengerSignal TransductionTranscriptional ActivationTumor Cells, CulturedDual-Specificity PhosphatasesDUSP22 protein, humanEstradiolEstrogen Receptor alphaMitogen-Activated Protein Kinase PhosphatasesPhosphoprotein PhosphatasesPhosphoserineProtein Tyrosine PhosphatasesRNA, Messenger

Identifiers

PMID17384676
OpenAlexW2019924027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.